Serono Laboratories Launches Comprehensive Website for Infertility Education and Support

Strategic Insights -

Serono Laboratories, the world's leading producer of drug therapies for infertility, has launched a comprehensive website dedicated to providing information and support to patients and healthcare providers. The website, www.infertilityresource.com, aims to promote patient education and empowerment, and includes interactive patient education sections, treatment options, and advocacy and support groups.

Key Takeaways:

  • The website, www.infertilityresource.com, has received a bronze excellence award from the Medical Marketing Association in recognition of its innovative design and content.
  • The website includes an interactive patient education section, descriptions of treatment options, listings of advocacy and support groups, and complete information on Serono's currently marketed U.S. drug therapies.
  • The site provides guidance on managing insurance claims for infertility treatment and includes a printable, personalized letter that patients can use to get a predetermination of their coverage.
  • Serono Connections, a range of patient support services, is also available through the website, providing telephone support lines for medical information, injection assistance, and other product information.
  • The website is part of a larger Serono website, www.seronousa.com, which includes information on other therapeutic areas served by the company, as well as a corporate section about Serono's extensive activities in biotech research and development, corporate news, and company history.
  • The website is designed to provide patients with the latest information about infertility in the privacy and security of their homes.

Statistics:

  • Over 800 websites from around the world were involved in the Medical Marketing Association's excellence award competition, of which www.infertilityresource.com received a bronze award.
  • Serono Laboratories has been the leading supplier of innovative drug therapies for infertility for over 30 years.
  • Gonal-F, a recombinant gonadotropin therapy, received marketing clearance in 1997 and is indicated for ovulation induction and use with assisted reproductive technologies such as in vitro fertilization.

Sources:

  • "Serono Laboratories Launches Comprehensive Website for Infertility Education and Support" (PR Newswire, October 6)
  • Medical Marketing Association (excellence award citation)
  • Serono Laboratories website (www.infertilityresource.com)
  • Hisham Samra, M.D., president of Serono Laboratories (quote)